STORY FROM: Drugs & Medical Devices
New Lawsuit Says Farxiga Makers Hid Risks of Ketoacidosis While Aggressively Marketing Drug in U.S.
June 6, 2016
ABERDEEN, Miss. — A Mississippi woman has accused the makers of type 2 diabetes drug Farxiga of aggressively marketing the drug while failing to warn consumers and doctors in the United States that it can cause diabetic ketoacidosis and kidney damage.
According to the complaint, originally filed in the Sunflower County (Miss.) Circuit Court, and removed to the Northern District of Mississippi on May 31, defendants Bristol-Myers Squibb Co. and AstraZeneca knew of the significant risks posed by Farxiga, yet touted it as safe and effective and paid thousands of doctors to prescribe the drug.
Farxiga (dapagliflozin), a sodium glucose ...
Associated Law Firms
Levin Papantonio Thomas Mitchell Rafferty & Proctor in Pensacola, Fla.